Skip to main content

Month: March 2026

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the fourth quarter and full year ended December 31, 2025. “The Company continues to execute at a high level, including recruitment of 143 patients in our ongoing Halneuron® Phase 2b trial, commencement of a Phase 2b extension trial and the recent execution of a financing to provide us with operational runway through the Phase 2b final data readout later this year,” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. Key HighlightsIn December 2025, the Company announced the results of an interim analysis of the Halneuron® Phase 2b trial. The independent statistical review committee...

Continue reading

Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results

Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval; Lifeward gains new oral protein delivery technology platform Lifeward already executing new strategy through acquisition of powered upper-body exoskeleton technology Lower operating expenses and cash usage reflect improved operational efficiency HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 18, 2026 (GLOBE NEWSWIRE) — Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the fourth quarter and full year ended December 31, 2025. “We are entering 2026 with a pivotal transaction that establishes...

Continue reading

One Stop Systems Reports Q4 2025 Results

Fourth quarter of 2025 revenue increased 70.2% year-over-year to $12.0 million, with record quarterly gross margin of 58.5% Net income from continuing operations of $2.0 million for 2025 fourth quarter Positive defense and commercial market demand is expected to support another strong year of revenue growth in 2026 ESCONDIDO, Calif., March 18, 2026 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (“OSS” or the “Company”) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML), autonomy and sensor processing at the edge, reported results for the fourth quarter ended December 31, 2025. Fourth quarter and twelve-month comparisons are to the same year-ago periods unless otherwise noted. On December 30, 2025, the Company closed a definitive agreement to sell...

Continue reading

Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

U.S. Patent Notice of Allowance for CTx-1301 Received; Additional European Patents Granted Recent $12M Private Placement Closed At-the-Market Pricing KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended December 31, 2025, and provided a corporate update. Highlights include recent U.S. and European patent developments, the closing of a $12 million private investment, and the acceptance of a New Drug Application (NDA) for its lead candidate, CTx-1301 (dexmethylphenidate HCl). Cingulate CEO Shane J. Schaffer stated, “Cingulate delivered on key inflection points throughout 2025...

Continue reading

Myseum Launches Affiliate Program for its Next-Gen Private Social Networking Platform Picture Party

Initiative aligned with Company’s monetization and growth strategies  NEW BRUNSWICK, N.J., March 18, 2026 (GLOBE NEWSWIRE) — Myseum, Inc. (Nasdaq: MYSE) (“Myseum” or the “Company”), a privacy-first social media and technology innovator, today announced the launch of an affiliate program focused on quickly building a large performance-based domestic and international salesforce. Initial target markets include large conferences, conventions, organizations, social gatherings, influencers, businesses and sporting events The Picture Party platform addresses the unmet need for private social networking that allows a user to almost instantly create a private social feed for sharing posts, pictures and videos. The patented technology enables users to capture and share many different perspectives and photos of events such as weddings and...

Continue reading

Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe

First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™, from one of the largest clinical laboratory chains operating across Europe. Strategic Account: This new lab’s scale and geographic reach across Europe positions it as a reference account and potential gateway to broader EU laboratory channel adoption. Repeat Order Potential: Based on the nature of the relationship, Biomerica believes this initial order will result in recurring orders as Hp Detect™ is integrated into the customer’s routine testing workflow. Disease Burden: H. pylori affects an estimated 45% of the population across Europe’s five largest countries. The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest threat to human health globally.IRVINE,...

Continue reading

Progressive Reports February 2026 Results

MAYFIELD VILLAGE, OHIO, March 18, 2026 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended February 28, 2026:  February(millions, except per share amounts and ratios; unaudited)   2026       2025     ChangeNet premiums written $ 6,995     $ 6,684     5   %Net premiums earned $ 6,528     $ 6,036     8   %Net income $ 943     $ 928     2   %Per share available to common shareholders $ 1.61     $ 1.58     2   %Total pretax net realized gains (losses) on securities $ (5 )   $ (110 )   (95 ) %Combined ratio   85.7       82.6     3.1   pts.Average diluted equivalent common shares   586.8       587.6     0   %  February 28,(thousands; unaudited) 2026   2025   % ChangePolicies in Force          Personal Lines          Agency – auto 10,959   9,950   10Direct...

Continue reading

OXB enters into licensing agreement with Viral Vector Manufacturing Facility (VVMF), providing access to its AAV and LV viral vector platforms

Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into a licensing and option agreement with Viral Vector Manufacturing Facility (VVMF), an Australian CDMO and the country’s first commercial manufacturing facility of its kind. Further to the non-binding terms sheet signed in October 2025, this agreement provides VVMF with a worldwide, non-exclusive licence to OXB’s proprietary inAAVate™ platform know-how and intellectual property, with an option to extend the licence to its proprietary LentiVector™ platform. In return, OXB will receive a low single-digit million licence fee and is eligible for future payments related to the use...

Continue reading

ROC to Ring the Nasdaq Closing Bell on March 19, 2026 in Celebration of its Public Listing

DENVER, CO, March 18, 2026 (GLOBE NEWSWIRE) — Rank One Computing Corporation d/b/a ROC, (Nasdaq: ROC) (“ROC” or the “Company”), a U.S. leader in multimodal Vision AI, building sovereign biometric, video analytics, and mission intelligence solutions into a unified platform, today announced the Company will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York, on Thursday, March 19, 2026, to celebrate its milestone listing on the Nasdaq Capital Market. With the support and financial flexibility provided by the capital markets, ROC is well-positioned to deliver on its growth strategy to further augment and scale its leading American Vision AI identity and intelligence platform. B. Scott Swann, CEO of ROC, will ring the Nasdaq closing bell, accompanied by ROC’s founders Brendan Klare and Josh Klontz, members...

Continue reading

Morris State Bancshares Announces Shareholder Approval and Special Pre-Closing Dividend

DUBLIN, Ga., March 18, 2026 (GLOBE NEWSWIRE) — Morris State Bancshares, Inc. (OTCQX: MBLU) (the “Company”), the parent company of Morris Bank, today announced that its shareholders have approved the proposed merger with Vallant Financial, Inc. The merger has also received all required regulatory approvals. In connection with the merger, the Company’s board has approved a Special Pre-Closing Dividend of $0.54 per share to all MBLU shareholders of record as of the close of business on March 24, 2026. The dividend will be payable on March 30, 2026. “We are extremely excited to continue building on the legacy that George Morris founded in downtown Dublin in 1954 with our merger to create Vallant,” said Spence Mullis, Chairman and CEO of Morris State Bancshares. “This milestone marks the beginning of Vallant Bank’s future—a continuation...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.